Preventive effect of 5% lidocaine patch on the development of neuropathic pain following an osteoporotic vertebral fracture: A proof-of-concept, controlled, randomized trial

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524889-25-00

Enrollment

Registered

2026-06-17

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporotic Fracture

Brief summary

Onset of neuropathic pain 2 months after enrollment, as a percentage of patients, using the Pain Detect Questionnaire (score ≥19).

Detailed description

Adverse effects and compliance in the daily logbook, Pain assessment (numerical scale) after 2 months of treatment, Concomitant treatments, Quality of life of patients according to SF36 and sleep according to PSQI, Psychophysical assessment in neuropathic patients

Interventions

DRUGVERSATIS 700 mg

DRUGemplâtre médicamenteux

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Onset of neuropathic pain 2 months after enrollment, as a percentage of patients, using the Pain Detect Questionnaire (score ≥19).	—

Secondary

Measure	Time frame
Adverse effects and compliance in the daily logbook, Pain assessment (numerical scale) after 2 months of treatment, Concomitant treatments, Quality of life of patients according to SF36 and sleep according to PSQI, Psychophysical assessment in neuropathic patients	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 18, 2026